What is the difference between a 503A pharmacy and a 503B outsourcing facility for semaglutide?
What is the difference between a 503A and 503B pharmacy for semaglutide?
A 503A pharmacy is a state-licensed pharmacy that compounds for an individual patient on a prescription, while a 503B outsourcing facility registers with FDA, is subject to FDA inspection and current good manufacturing practice requirements, and appears on FDA’s public list (100 facilities on Nov 6, 2026). For semaglutide, FDA stated on April 1, 2026 that outsourcing facilities may compound from the bulk drug only if it is on the 503B bulks list or the shortage list, neither of which applied, and that 503A pharmacies may not regularly compound essentially copies of an approved drug.
A plain description of two record types. It is not legal or medical advice.
What the public records show for each
| Record | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Who licenses or registers it | State board of pharmacy | FDA registration, plus state licenses where required |
| Public FDA list of all facilities | None | 100 registered facilities |
| Entries on FDA’s compounding actions list | 317 | 74 |
| Form 483s on that list | 243 | 192 |
| Warning letters on that list | 72 | 37 |
| GLP-1 warning letters in this index matched by name | 9 | 6 |
Counts come from FDA’s compounding inspections and actions page (current as of Oct 22, 2026), which covers actions from 2019 on, and this index. The counts reflect which facilities FDA inspected or acted on and posted; they are not a comparison of quality.
FDA’s statements, by date
- Feb 21, 2025: FDA determined that the shortage of semaglutide injection products is resolved. FDA said it did not intend to take action, for violations that depend on semaglutide being on the shortage list, against 503A pharmacies and physicians until April 22, 2025, or 503B outsourcing facilities until May 22, 2025 (or a pending court decision, whichever was later). The same update listed liraglutide injection as in shortage. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 24, 2025: A federal district court denied the preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.). FDA stated (update dated April 28, 2025) that the enforcement discretion period for 503A semaglutide compounding had ended, and that for 503B outsourcing facilities it ran until May 22, 2025. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 1, 2026: FDA stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list. FDA explained that outsourcing facilities may compound from bulk drug substances only if the substance is on the 503B bulks list or the drug is on the shortage list at the time of compounding, distribution and dispensing. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 1, 2026: FDA restated the section 503A conditions: compounding for an individual patient on a prescription, and not compounding regularly or in inordinate amounts drugs that are essentially copies of a commercially available drug. FDA gave semaglutide combined with vitamin B12 (cyanocobalamin) as an example that may be considered essentially a copy, and said that at this time it does not intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 30, 2026: FDA announced a proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound them from bulk drug substances. FDA said it would consider public comments before a final determination. Source: FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
Common questions
Can a 503B outsourcing facility make semaglutide now?
FDA stated on April 1, 2026 that outsourcing facilities may compound from bulk drug substances only if the substance is on the 503B bulks list or the drug is on the shortage list, and that semaglutide was on neither. On April 30, 2026 FDA proposed not adding semaglutide to the bulks list; no final determination appears in the Federal Register docket in this index.
Can a 503A pharmacy compound semaglutide?
FDA’s April 1, 2026 statement restates the 503A conditions: compounding for an individual patient on a prescription, and not regularly or in inordinate amounts making essentially copies of a commercially available drug. FDA gave semaglutide with vitamin B12 as an example that may be considered essentially a copy.
How do I check which kind a pharmacy is?
Look for it on FDA’s 503B list. If it is not there, it is not a registered outsourcing facility, and its license comes from a state board of pharmacy.
Sources
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
Records last pulled Nov 15, 2026. Every entry links to the original public record.